Lipitor Generics: Judge Questions Mylan's Right To Sue Over Ranbaxy Marketing Exclusivity
This article was originally published in PharmAsia News
Executive Summary
Questions during an April 28 court hearing suggest Mylan Pharmaceuticals Inc. may have a difficult time persuading a federal judge that it has standing, at this time, to force an FDA determination on generic marketing exclusivity rights for Pfizer's Lipitor
You may also be interested in...
Lipitor Generics: Ranbaxy Still In The Driver's Seat As Court Dismisses Mylan Lawsuit Against U.S. FDA
Two unresolved factual matters stand in the way of Mylan Pharmaceuticals Inc.' s bid to sue U.S. FDA over generic marketing exclusivity for Pfizer's Lipitor, a U.S. federal judge ruled May 2
Lipitor Generics: Ranbaxy Still In The Driver's Seat As Court Dismisses Mylan Lawsuit Against U.S. FDA
Two unresolved factual matters stand in the way of Mylan Pharmaceuticals Inc.' s bid to sue U.S. FDA over generic marketing exclusivity for Pfizer's Lipitor, a U.S. federal judge ruled May 2
Fight For Lipitor: FDA Calls For Dismissal Of Mylan's Plea On Ranbaxy's AIP
MUMBAI - The U.S. Food and Drug Administration has filed for dismissal of Mylan's March 18 motion that sought a declaratory judgement to enforce provisions of the Application Integrity Policy against Ranbaxy, calling for an immediate denial of the ANDA for Pfizer's leading cholesterol-lowering agent Lipitor (atorvastatin) to the Indian company